221 related articles for article (PubMed ID: 37605654)
1. Growth hormone proteoformics atlas created to promote predictive, preventive, and personalized approach in overall management of pituitary neuroendocrine tumors.
Yang L; Li C; Song T; Zhan X
EPMA J; 2023 Sep; 14(3):443-456. PubMed ID: 37605654
[TBL] [Abstract][Full Text] [Related]
2. Human growth hormone proteoform pattern changes in pituitary adenomas: Potential biomarkers for 3P medical approaches.
Li B; Wang X; Yang C; Wen S; Li J; Li N; Long Y; Mu Y; Liu J; Liu Q; Li X; Desiderio DM; Zhan X
EPMA J; 2021 Mar; 12(1):67-89. PubMed ID: 33786091
[TBL] [Abstract][Full Text] [Related]
3. Personalized Drug Therapy: Innovative Concept Guided With Proteoformics.
Su J; Yang L; Sun Z; Zhan X
Mol Cell Proteomics; 2024 Mar; 23(3):100737. PubMed ID: 38354979
[TBL] [Abstract][Full Text] [Related]
4. Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine.
Bajinka O; Ouedraogo SY; Golubnitschaja O; Li N; Zhan X
EPMA J; 2024 Jun; 15(2):289-319. PubMed ID: 38841622
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
6. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects.
Doga M; Bonadonna S; Burattin A; Giustina A
Ann Oncol; 2001; 12 Suppl 2():S89-94. PubMed ID: 11762359
[TBL] [Abstract][Full Text] [Related]
7. Clinical review 112: Does serum growth hormone (GH) binding protein reflect human GH receptor function?
Amit T; Youdim MB; Hochberg Z
J Clin Endocrinol Metab; 2000 Mar; 85(3):927-32. PubMed ID: 10720017
[TBL] [Abstract][Full Text] [Related]
8. Mass spectrometry-based proteomics analyses of post-translational modifications and proteoforms in human pituitary adenomas.
Li J; Zhan X
Biochim Biophys Acta Proteins Proteom; 2021 Mar; 1869(3):140584. PubMed ID: 33321259
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.
Kola B; Korbonits M; Diaz-Cano S; Kaltsas G; Morris DG; Jordan S; Metherell L; Powell M; Czirják S; Arnaldi G; Bustin S; Boscaro M; Mantero F; Grossman AB
Clin Endocrinol (Oxf); 2003 Sep; 59(3):328-38. PubMed ID: 12919156
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of membrane associated-growth hormone binding protein (MA-GHBP) and growth hormone receptor (GHR) expression by growth hormone (GH) in mouse liver.
González L; Curto LM; Miquet JG; Bartke A; Turyn D; Sotelo AI
Growth Horm IGF Res; 2007 Apr; 17(2):104-12. PubMed ID: 17321774
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone receptor synthesis and release in tumorous somatolactotrophs.
Hull KL; Sanders EJ; Harvey S
Endocrine; 1995 Jun; 3(6):461-7. PubMed ID: 21153251
[TBL] [Abstract][Full Text] [Related]
13. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.
Zhou C; Jiao Y; Wang R; Ren SG; Wawrowsky K; Melmed S
J Clin Invest; 2015 Apr; 125(4):1692-702. PubMed ID: 25774503
[TBL] [Abstract][Full Text] [Related]
14. Severe growth failure associated with a novel heterozygous nonsense mutation in the GHR transmembrane domain leading to elevated growth hormone binding protein.
Rughani A; Zhang D; Vairamani K; Dauber A; Hwa V; Krishnan S
Clin Endocrinol (Oxf); 2020 Apr; 92(4):331-337. PubMed ID: 31883394
[TBL] [Abstract][Full Text] [Related]
15. An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism.
Asa SL; Ezzat S
J Clin Med; 2021 May; 10(11):. PubMed ID: 34067494
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone binding protein 2001.
Baumann G
J Pediatr Endocrinol Metab; 2001 Apr; 14(4):355-75. PubMed ID: 11327370
[TBL] [Abstract][Full Text] [Related]
17. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor.
Thorner MO; Perryman RL; Cronin MJ; Rogol AD; Draznin M; Johanson A; Vale W; Horvath E; Kovacs K
J Clin Invest; 1982 Nov; 70(5):965-77. PubMed ID: 6290540
[TBL] [Abstract][Full Text] [Related]
18. Guinea pig serum contains a specific high affinity growth hormone-binding protein with novel ligand specificity.
Ymer SI; Stevenson JL; Herington AC
Endocrinology; 1997 Sep; 138(9):3577-86. PubMed ID: 9275038
[TBL] [Abstract][Full Text] [Related]
19. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
20. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
